CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Minocyclinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02213575
NCT02213575Phase 2Completed
CompareCT.gov

Study 3: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

University of Florida·interventional·Posted Aug 11, 2014·Updated Jul 1, 2025

In Brief

A Phase 2 clinical trial evaluating Minocycline for Hypertension. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This study is a mechanistic study that will enroll 9 subjects who are participating in NCT02133872 (which is designed to evaluate minocycline to test the hypothesis that minocycline treatment would produce antihypertensive effects in drug-resistant neurogenic hypertensive individuals) to test whether the antihypertensive effect of minocycline is associated with a decrease in activated microglia in central nervous system autonomic regions as evidenced by changes in PET and MRI imaging.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 11, 2014
Enrollment StartMar 5, 2016
Primary CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.9 years ago

Interventions

Minocyclinedrug

Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and 26 week follow-up MRI and PET scans for changes in the paraventricular nucleus.